Earn CME/CE in your profession:

Continuing Education Activity

Methylphenidate is FDA-approved for treating attention deficit hyperactivity disorder (ADHD) in children and adults and as a second-line treatment for narcolepsy in adults. Children diagnosed with ADHD should be at least six years of age or older before being started on this medication. Off-label uses of methylphenidate include treatment for fatigue in patients with cancer, refractory depression in the geriatric population, apathy in Alzheimer's disease, and enhancing cognitive performance (e.g., memory). The efficacy of methylphenidate for its off-label uses varies from limited to moderate. This activity will highlight the mechanism of action, adverse event profile/toxicity, pharmacology, monitoring, relevant interactions, and street names of methylphenidate, pertinent for interprofessional team members should they encounter a patient who requires therapy with or has potentially misused this drug.


  • Review the mechanism of action of methylphenidate.
  • Identify the approved and off-label uses of methylphenidate.
  • Summarize the contraindications and adverse events associated with methylphenidate.
  • Describe interprofessional team strategies for improving care coordination and communication to properly use methylphenidate to improve patient outcomes in the varied scenarios where it can be effective.


Methylphenidate is FDA-approved for treating attention deficit hyperactivity disorder (ADHD) in children and adults and as a second-line treatment for narcolepsy in adults.[1][2] 

Children diagnosed with ADHD should be at least six years of age or older before being started on this medication. The treatment of both ADHD and narcolepsy have significantly better outcomes when used concurrently with nonpharmacologic therapies (i.e., social skills training in ADHD or sleep hygiene measures in narcolepsy). 

Off-label uses of methylphenidate include treatment for fatigue in patients with cancer, refractory depression in the geriatric population, apathy in Alzheimer disease, and enhancing cognitive performance (e.g., memory).[3][4][5][6][7][8] Since it can be abused as a cognitive enhancer, it is a federally controlled Schedule II substance. The efficacy of methylphenidate for its off-label uses varies from limited to moderate. Most of these relatively newer uses are still being studied and implemented into clinical practice.

Mechanism of Action

Methylphenidate blocks the reuptake of two neurotransmitters, norepinephrine (NE) and dopamine, in presynaptic neurons. More specifically, it inhibits the transporters of these neurotransmitters, increasing the concentration of dopamine and NE in the synaptic cleft.[9] This creates its classic stimulant effect within the central nervous system (CNS), mainly in the prefrontal cortex. It chemically derives from phenethylamine and benzylpiperazine. It undergoes metabolism by the liver to ritalinic acid through a process called de-esterification via carboxylesterase CES1A1. Compared to other medications (i.e., amphetamines) that are phenethylamine derivatives, methylphenidate appears to increase the firing rate of neurons.[10] It is also a weak agonist at the 5HT1A receptor, which is an additional mechanism that contributes to the increased levels of dopamine.[11] 

With the increase in dopamine levels, methylphenidate can provide neuroprotection in certain conditions like Parkinson disease, which involves loss of dopaminergic neurons and methamphetamine abuse.[12] This effect occurs not only through its direct inhibition of the dopamine transporter but also via indirect regulation of the vesicular monoamine transporter 2. The combined interactions methylphenidate has on both of these transporters reduce the amount of dopamine that accumulates within the cytoplasm in patients with these conditions, thereby preventing the formation of reactive oxygen species that would otherwise be dangerously toxic to the brain. 


The therapeutic dosages for ADHD or narcolepsy that physicians prescribe are not harmful enough to activate the reward system within the CNS, known as the nucleus accumbens. However, excessively higher dosages taken by those who intentionally abuse the drug lead to an overexpression of deltaFosB, a transcriptional activator, in specific neurons within the striatum. This accumulation of deltaFosB in the nucleus accumbens activates a series of signaling cascades that further triggers the addiction.[13]


  • Absorption: Slow but extensive; relative bioavailability for extended-release tablets 105% in children and 101% in adults (verses immediate-release tablets); the absolute oral bioavailability for extended-release capsules in children was 22% and 5% for d-methylphenidate and l-methylphenidate, respectively. 
  • Time of peak plasma concentration: 1.9 hours for immediate-release tablets and 4.7 hours for extended-release tablets
  • Food effects: Increase total exposure and peak plasma concentration; reduce the time for peak plasma concentration for extended-release tablets.
  • Alcohol effect: 98% of the drug from extended-release 40 mg capsule dosage form was released in an alcohol concentration of 40% in an in-vitro study.
  • Distribution: Volume of distribution was 2.65 and 1.80 L/kg for d- methylphenidate and l- methylphenidate, respectively.
  • Plasma Protein Binding: 10% to 33%
  • Metabolism: It is primarily metabolized by de-esterification to ritalinic acid, which is pharmacologically inactive.
  • Excretion: A majority of the drug (78% to 97%) is excreted in the urine, while small amounts are excreted in feces.


For medical purposes, methylphenidate is mainly given orally or, less commonly, as a transdermal patch. Multiple oral formulations are available that categorize according to how quickly the drug is released: immediate (IR), extended (XR or ER), and sustained. Two of the more unique formulations of methylphenidate are its ER sphenoidal oral drug absorption system that has a bimodal release and the osmotic (controlled) release delivery system. There are chewable tablets (either IR or ER) for children and an IR solution. Doses should not exceed 72 mg, the maximum dose of the ER tablet. If using the transdermal patch, the patient must be aware of placing the patch on the opposite hip each time to achieve its full effect. Those who misuse methylphenidate for recreational purposes prefer to use the intravenous (IV) or the intranasal route. Assess the risk of abuse before prescribing methylphenidate in any form.

Available Dosage Forms and Strengths 

  • Attention deficit disorder (ADD) in adults and pediatric patients (6 years and older) and for narcolepsy
    • Chewable tablets: 2.5 mg, 5 mg, and 10 mg
    • Immediate-release tablets: 5 mg, 10 mg, and 20 mg
  • Attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients (6 years and older) and for narcolepsy
    • Immediate-release tablets: 5 mg, 10 mg, and 20 mg
    • Extended-release tablets: 10 mg, 20 mg, 18 mg, 27 mg, 36mg, 54 mg, and 72 mg
    • Extended-release tablets (24 hours): 18 mg, 27 mg, 36mg, and 54 mg
    • Extended-release capsules: 10 mg, 20 mg, 30 mg, and 40 mg
    • Extended-release capsules CD: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg
    • Solution: 5 mg/ 5 ml and 10 mg / 5 ml in 500 ml bottle
    • ADHD in adults and pediatric patients (6 years and older) as well as for narcolepsy
  • Attention deficit hyperactivity disorder (ADHD) in pediatric patients (age 6 to 17 years)
    • Orally disintegrating tablets: 8.6 mg, 13.7 mg, and 25.9 mg
    • Patch: 10 mg, 15 mg, 20 mg, and 30 mg nominal dose over 9 hours

 Specific Patients Population 

  • Patient with Hepatic Impairment: There is no dose adjustment guidance in the manufacturer label for patients with hepatic impairment.
  • Patient with Renal Impairment: There is no dose adjustment guidance in the manufacturer label for patients with renal impairment. However, most of the drug and its metabolites are excreted in the urine. 
  • Pregnant Women: It is considered as pregnancy category C medicine. Many researchers studied methylphenidate during pregnancy to treat ADHD and narcolepsy, However, data is conflicting so use the medication with caution.[14][15][16][17]
  • Breastfeeding Women: It is recommended to monitor and keep relative infant dose below 10% while using methylphenidate therapy in nursing mothers as the drug is present in breast milk.[18][19]
  • Pediatric Patients: There are multiple dosage forms and strengths available for pediatric patients ages ranging from 6 years to 17 years.
  • Geriatric Patients: There is no specific dose adjustment guidance available.

Adverse Effects

Insomnia and nervousness are the most commonly reported adverse effects in patients using methylphenidate.[20]

Growth retardation (decreased height, weight, and bone marrow density) is observed when taken long-term in children.[21]

Other frequent side effects mainly involve the CNS (dizziness, headache, tics, restlessness/akathisia), gastrointestinal (nausea/vomiting, dry mouth, decreased appetite, weight loss, abdominal pain), and cardiovascular systems (tachycardia, and palpitations).

Dermatologically, patients can complain of excessive sweating and ulceration of their digits.

Some patients may even develop blurry vision or decreased libido. While it rarely occurs, priapism is a medical emergency that requires immediate attention.[20] 

Patients are more prone to become easily agitated, irritable, or depressed and go through mood swings/lability.

While many common side effects can be relieved by adjusting the dosage or avoiding an afternoon or evening dose, some require treatment emergently to prevent complications.

It is important to note that there have been reported cases of sudden death in both children and adults with a pre-existing structural cardiac abnormality.[22] Stroke and myocardial infarction also have been observed in adults. Due to the risk of such fatal side effects, it is advisable to avoid methylphenidate in patients with a structural cardiac abnormality, cardiomyopathy, or arrhythmias.[23]

Drug Interactions: Methylphenidate can inhibit the metabolism of warfarin, phenytoin, tricyclic antidepressants, or SSRIs and can increase plasma concentration.


Patients must not use methylphenidate if they are currently on monoamine oxidase inhibitors (MAOIs). There should be a minimum of at least 14 days after discontinuation of MAOIs before methylphenidate can be considered a safe treatment option to begin due to the risk of hypertensive crisis.

Medical conditions that are not compatible with methylphenidate include glaucoma, severe hypertension, motor tics, Tourette syndrome, or a family history of Tourette syndrome.

If a patient is noticeably anxious, tense, or agitated, then seek alternative treatment options. However, it can be given cautiously in patients with a history of bipolar disorder or psychosis as long as clinicians are wary of mania or psychotic episodes induced by the medication.[12]

Any patient who develops a hypersensitive reaction to methylphenidate or an individual component of a formulation should have the medication immediately discontinued and switch to another pharmacologic agent.

Children under the age of six should not be prescribed this medication as there are limited studies to prove its safety or benefit, and it could cause learning impairments.


Since it has the potential risk of abuse, monitor patients for signs of dependence and or abuse while on therapy.

A complete blood count with differential should be obtained periodically for those on methylphenidate.

The main vitals to note at each visit are blood pressure and heart rate, especially in patients with underlying hypertension, heart failure, a recent MI, or ventricular arrhythmia, as slight elevations can occur with methylphenidate use. In addition, if a patient complains of cardiac symptoms, such as chest pain, that worsens with exertion or has a near-syncope episode, then a full cardiac workup should be performed.

In children, it is essential to evaluate their growth curve for a stable progression in height, and weight since methylphenidate has demonstrated growth suppression when used daily, long-term. The medication should either be readjusted or discontinued if children are not in a healthy percentile on their growth curve.[21]

Clinicians should screen for symptoms of depression, agitation, aggressiveness, new-onset or pre-existing psychosis or mania, and suicidality as these can be worsened when initially starting methylphenidate. Physicians should also monitor for signs of intravenous abuse as frank psychotic episodes can develop.

On physical exam, look for peripheral vasculitis (digital ulceration). 

Controversial evidence exists regarding the potential for methylphenidate to affect seizure threshold. If seizures develop while being treated with methylphenidate, the prescribing clinician should immediately stop the drug.[24][25]

In adults, patients should limit their alcohol use while taking methylphenidate as its stimulant action can mask the actual sedative effect caused by alcohol intoxication, possibly inducing severe respiratory depression.

Additionally, a patient who is concurrently on warfarin, phenytoin, tricyclic antidepressants, or SSRIs should have their drug levels monitored and adjust doses as needed to achieve a therapeutic effect.


The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the IR (immediate-release) formulation or 120 mg of the ER (extended-release) formulation can be considered toxic. If the overdosed quantity is unknown, look for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, IV fluids and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present.[20]

Enhancing Healthcare Team Outcomes

It is essential to gather a thorough history from the patient (or patient’s legal guardian) regarding their past medical history, current medications, and social history (obtain a developmental history if the patient is a child). An interprofessional healthcare team consisting of the patient’s primary care provider, psychiatrist, nurse practitioners, physician assistants, social workers, therapists, school teachers, and pharmacists should oversee the patient case. Communication between each member of the healthcare team is crucial as medication combined with non-pharmacologic treatment measures provide the most long-term success. Evaluation of side effects requires close monitoring at each visit. If the patient is a child, it is crucial to give patient’s legal guardian education regarding the medication and its side effects. This interprofessional approach will optimize therapeutic results while limiting adverse events. [Level 5]


Studies have shown that medication alone is not as effective as when methylphenidate is combined with non-pharmacologic treatment measures. Patients with ADHD managed on both medication, and non-pharmacologic treatments have been shown to have higher self-esteem and social functioning skills versus those untreated. Long-term beneficial effects have been shown in adults with ADHD who continue to take methylphenidate. Further long-term studies are still in progress.[26][27]

Article Details

Article Author

Corinne Verghese

Article Editor:

Sara Abdijadid


1/12/2022 11:34:15 AM

PubMed Link:




Methylphenidate off-label use and safety., Trenque T,Herlem E,Abou Taam M,Drame M,, SpringerPlus, 2014     [PubMed PMID: 25279275]


The Medical and Economic Burden of Narcolepsy: Implications for Managed Care., Thorpy MJ,Hiller G,, American health & drug benefits, 2017 Jul     [PubMed PMID: 28975007]


Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities, Theleritis C,Siarkos K,Katirtzoglou E,Politis A,, Journal of geriatric psychiatry and neurology, 2017 Jan     [PubMed PMID: 28248559]


A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients., Escalante CP,Meyers C,Reuben JM,Wang X,Qiao W,Manzullo E,Alvarez RH,Morrow PK,Gonzalez-Angulo AM,Wang XS,Mendoza T,Liu W,Holmes H,Hwang J,Pisters K,Overman M,Cleeland C,, Cancer journal (Sudbury, Mass.), 2014 Jan-Feb     [PubMed PMID: 24445757]


The use of methylphenidate to relieve fatigue., Rojí R,Centeno C,, Current opinion in supportive and palliative care, 2017 Dec     [PubMed PMID: 28885263]


The problem of fatigue in patients suffering from neoplastic disease., Kolak A,Kamińska M,Wysokińska E,Surdyka D,Kieszko D,Pakieła M,Burdan F,, Contemporary oncology (Poznan, Poland), 2017     [PubMed PMID: 28947882]


Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial., Lavretsky H,Reinlieb M,St Cyr N,Siddarth P,Ercoli LM,Senturk D,, The American journal of psychiatry, 2015 Jun     [PubMed PMID: 25677354]


Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis., Ilieva IP,Hook CJ,Farah MJ,, Journal of cognitive neuroscience, 2015 Jun     [PubMed PMID: 25591060]


Methylphenidate HCl: therapy for attention deficit hyperactivity disorder., Capp PK,Pearl PL,Conlon C,, Expert review of neurotherapeutics, 2005 May     [PubMed PMID: 15938665]


Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling., Viggiano D,Vallone D,Sadile A,, Neural plasticity, 2004     [PubMed PMID: 15303308]


The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor., Markowitz JS,DeVane CL,Ramamoorthy S,Zhu HJ,, Die Pharmazie, 2009 Feb     [PubMed PMID: 19322953]


The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people., Sahakian BJ,Bruhl AB,Cook J,Killikelly C,Savulich G,Piercy T,Hafizi S,Perez J,Fernandez-Egea E,Suckling J,Jones PB,, Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015 Sep 19     [PubMed PMID: 26240429]


Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens., Kim Y,Teylan MA,Baron M,Sands A,Nairn AC,Greengard P,, Proceedings of the National Academy of Sciences of the United States of America, 2009 Feb 24     [PubMed PMID: 19202072]


Baker AS,Freeman MP, Management of Attention Deficit Hyperactivity Disorder During Pregnancy. Obstetrics and gynecology clinics of North America. 2018 Sep     [PubMed PMID: 30092924]


Damkier P, Methylphenidate and pregnancy. British journal of clinical pharmacology. 2014 Jun     [PubMed PMID: 24003978]


Calvo-Ferrandiz E,Peraita-Adrados R, Narcolepsy with cataplexy and pregnancy: a case-control study. Journal of sleep research. 2018 Apr     [PubMed PMID: 28568319]


Maurovich-Horvat E,Kemlink D,Högl B,Frauscher B,Ehrmann L,Geisler P,Ettenhuber K,Mayer G,Peraita-Adrados R,Calvo E,Lammers GJ,Van der Heide A,Ferini-Strambi L,Plazzi G,Poli F,Dauvilliers Y,Jennum P,Leonthin H,Mathis J,Wierzbicka A,Puertas FJ,Beitinger PA,Arnulf I,Riha RL,Tormášiová M,Slonková J,Nevšímalová S,Sonka K,European Narcolepsy Network., Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. Journal of sleep research. 2013 Oct;     [PubMed PMID: 23560595]


Bolea-Alamanac BM,Green A,Verma G,Maxwell P,Davies SJ, Methylphenidate use in pregnancy and lactation: a systematic review of evidence. British journal of clinical pharmacology. 2014 Jan;     [PubMed PMID: 23593966]


Ornoy A, Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation. Pharmaceutical research. 2018 Feb 6     [PubMed PMID: 29411149]


Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management., Spiller HA,Hays HL,Aleguas A Jr,, CNS drugs, 2013 Jul     [PubMed PMID: 23757186]


Poulton AS,Bui Q,Melzer E,Evans R, Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. International clinical psychopharmacology. 2016 Mar     [PubMed PMID: 26544899]


Nissen SE, ADHD drugs and cardiovascular risk. The New England journal of medicine. 2006 Apr 6     [PubMed PMID: 16549404]


Liu H,Feng W,Zhang D, Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. European child     [PubMed PMID: 30143889]


Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy., Liu X,Carney PR,Bussing R,Segal R,Cottler LB,Winterstein AG,, Journal of child and adolescent psychopharmacology, 2017 Oct 13     [PubMed PMID: 29028437]


Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence., Ravi M,Ickowicz A,, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 2016 Winter     [PubMed PMID: 27047557]


Harpin V,Mazzone L,Raynaud JP,Kahle J,Hodgkins P, Long-Term Outcomes of ADHD: A Systematic Review of Self-Esteem and Social Function. Journal of attention disorders. 2016 Apr;     [PubMed PMID: 23698916]


Fredriksen M,Peleikis DE, Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study. Basic     [PubMed PMID: 26404187]